PURPOSE: To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity. DESIGN: Observational case series. METHODS: Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties. RESULTS: In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication. CONCLUSIONS: Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
PURPOSE: To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity. DESIGN: Observational case series. METHODS: Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties. RESULTS: In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication. CONCLUSIONS:Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
Authors: Frank L Brodie; Emily S Charlson; Tomas S Aleman; Rebecca T Salvo; Dina Y Gewaily; Marisa K Lau; Neil D Farren; Stephanie B Engelhard; Maxwell Pistilli; Alexander J Brucker Journal: Retina Date: 2015-02 Impact factor: 4.256